Serum midkine level might be a diagnostic tool for COVID19 disease in pregnancy: From the disease severity, hospitalization and disease progression respects

Yazıhan, Nuray; Erol, Seyit Ahmet; Akdas, Sevginur; Ayhan, Şule Göncü; Atalay, Altay; Yıldırım, Muradiye; Biriken, Derya; Akin, İrem; Ceylan, Merve Nur; Keskin, Hüseyin Levent; Tekın, Özlem Moraloğlu; Şahın, Dilek

doi:10.1016/j.cyto.2021.155751

Cited by 6 publications

(6 citation statements)

References 36 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, another investigation described MK protein upregulation in sera of pregnant women with COVID-19, which was associated with pregnancy complications ( 126 ). In a similar study, MK serum levels in pregnant women with COVID-19 displayed a significant increase in contrast to healthy pregnant women ( 127 ). This augmented MK expression was significant throughout all trimesters ( 127 ).…”

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 65%

“…In a similar study, MK serum levels in pregnant women with COVID-19 displayed a significant increase in contrast to healthy pregnant women ( 127 ). This augmented MK expression was significant throughout all trimesters ( 127 ). The mild group had profoundly lower MK levels when compared to the moderate or severe group ( 127 ).…”

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 65%

“…The mild group had profoundly lower MK levels when compared to the moderate or severe group ( 127 ). Also, MK levels positively correlated with disease severity and hospitalization length and negatively with the oxygen saturation ( 127 ). Hence, MK was upregulated in COVID-19 patients.…”

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 89%

“…This augmented MK expression was significant throughout all trimesters ( 127 ). The mild group had profoundly lower MK levels when compared to the moderate or severe group ( 127 ). Also, MK levels positively correlated with disease severity and hospitalization length and negatively with the oxygen saturation ( 127 ).…”

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 91%

See 3 more Smart Citations

Midkine—A novel player in cardiovascular diseases

Majaj

Weckbach

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Midkine (MK) is a 13-kDa heparin-binding cytokine and growth factor with anti-apoptotic, pro-angiogenic, pro-inflammatory and anti-infective functions, that enable it to partake in a series of physiological and pathophysiological processes. In the past, research revolving around MK has concentrated on its roles in reproduction and development, tissue protection and repair as well as inflammatory and malignant processes. In the recent few years, MK's implication in a wide scope of cardiovascular diseases has been rigorously investigated. Nonetheless, there is still no broadly accepted consensus on whether MK exerts generally detrimental or favorable effects in cardiovascular diseases. The truth probably resides somewhere in-between and depends on the underlying physiological or pathophysiological condition. It is therefore crucial to thoroughly examine and appraise MK's participation in cardiovascular diseases. In this review, we introduce the MK gene and protein, its multiple receptors and signaling pathways along with its expression in the vascular system and its most substantial functions in cardiovascular biology. Further, we recapitulate the current evidence of MK's expression in cardiovascular diseases, addressing the various sources and modes of MK expression. Moreover, we summarize the most significant implications of MK in cardiovascular diseases with particular emphasis on MK's advantageous and injurious functions, highlighting its ample diagnostic and therapeutic potential. Also, we focus on conflicting roles of MK in a number of cardiovascular diseases and try to provide some clarity and guidance to MK's multifaceted roles. In summary, we aim to pave the way for MK-based diagnostics and therapies that could present promising tools in the diagnosis and treatment of cardiovascular diseases.

show abstract

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 65%

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 65%

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 89%

Section: Discussion: Midkine In Cardiovascular Diseasesmentioning

confidence: 91%

See 2 more Smart Citations

Midkine—A novel player in cardiovascular diseases

Majaj

Weckbach

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Studies indicate that MK, or a combined biomarker test that includes MK, outperforms other current serum biomarkers in detecting malignancies at an early stage [13][14][15]. In COVID-19, high levels of MK have been linked to more severe illness and worse outcomes [16,17]. However, the current scientific literature is inadequate in identifying the specific immune subpopulations affected by MK in NPC and COVID-19 infections.…”

Section: Introductionmentioning

confidence: 99%

Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19

Kam,

Lau,

Che

et al. 2023

Cancers

View full text Add to dashboard Cite

Clinical evidence suggests that the severe respiratory illness coronavirus disease 2019 (COVID-19) is often associated with a cytokine storm that results in dysregulated immune responses. Prolonged COVID-19 positivity is thought to disproportionately affect cancer patients. With COVID-19 disrupting the delivery of cancer care, it is crucial to gain momentum and awareness of the mechanistic intersection between these two diseases. This review discusses the role of the cytokine midkine (MK) as an immunomodulator in patients with COVID-19 and nasopharyngeal carcinoma (NPC), both of which affect the nasal cavity. We conducted a review and analysis of immunocellular similarities and differences based on clinical studies, research articles, and published transcriptomic datasets. We specifically focused on ligand–receptor pairs that could be used to infer intercellular communication, as well as the current medications used for each disease, including NPC patients who have contracted COVID-19. Based on our findings, we recommend close monitoring of the MK axis to maintain the desirable effects of therapeutic regimens in fighting both NPC and COVID-19 infections.

show abstract